Migraine
Conditions
Interventions
control group:Placebo
Sponsors
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Between the ages of 18 and 55 years (the first migraine is less than 50), regardless of gender, and with six or more years of education; 2. The patients met the diagnostic criteria for ICHD-3 migraines without aura; 3. In the last three months, the number of migraine attacks per month was more than 2 times, and the number of headache days per month was less than 15 days; 4. Migraines were moderate at baseline (mean VAS score 3-7); 5. Have a history of migraines for more than one year; 6. Patients who were able to complete the baseline headache diary; 7. The patient signed the informed consent; Note: only patients who meet the above 7 criteria can be included in this study.
Exclusion criteria
Exclusion criteria: 1. Patients with other primary headache and headache with unknown diagnosis; 2. Patients with severe primary diseases such as cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic system, and other organic diseases; 3. Patients with a history of head trauma and mental and mental disorders who were unable to respond to the questionnaire; 4. The patient that has haemorrhage tendency, allergic constitution person and skin disease; 5. Pregnant women and lactating women, who have the requirement of childbirth in the past 5 months; 6. Patients who cannot understand or keep a headache diary; 7. The patient who has the habit of taking analgesics, alcohol and so on for a long time; 8. Patients who had received acupuncture or other preventive therapy within the last 4 weeks; 9. Patients who had participated in a similar study within 3 months; Note: patients who meet any of the above criteria should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of migraine attacks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Migraine Specific Quality of Life Question, MSQ;Calcitonin Gene related Peptide, CGRP;Intensity of migraine;Treatment response rate;Headache impact scale (HIT-6);Headache duration (hours);Patient treatment satisfaction evaluation;TCM syndrome assessment scale;Days of migraine attack;Percentage of patients taking acute analgesic; | — |
Countries
China
Contacts
Public ContactZhao Yonglie
The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
Outcome results
None listed